[go: up one dir, main page]

CL2009001956A1 - Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer. - Google Patents

Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Info

Publication number
CL2009001956A1
CL2009001956A1 CL2009001956A CL2009001956A CL2009001956A1 CL 2009001956 A1 CL2009001956 A1 CL 2009001956A1 CL 2009001956 A CL2009001956 A CL 2009001956A CL 2009001956 A CL2009001956 A CL 2009001956A CL 2009001956 A1 CL2009001956 A1 CL 2009001956A1
Authority
CL
Chile
Prior art keywords
vitamin
composition
folic acid
disease
manufacturing
Prior art date
Application number
CL2009001956A
Other languages
English (en)
Inventor
Quiñones Luis
Maccioni Ricardo
Saavedra Ivan
Sandoval Victor
Sandoval Ricardo
Original Assignee
Neuroinnovation Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroinnovation Spa filed Critical Neuroinnovation Spa
Priority to CL2009001956A priority Critical patent/CL2009001956A1/es
Publication of CL2009001956A1 publication Critical patent/CL2009001956A1/es
Priority to CA2776919A priority patent/CA2776919C/en
Priority to GB1207939.8A priority patent/GB2487871B/en
Priority to PCT/CL2010/000043 priority patent/WO2011041920A2/es
Priority to US13/496,140 priority patent/US8784804B2/en
Priority to AU2010305251A priority patent/AU2010305251B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICIÓN NUTRACÉUTICA PODEROSA ANTIOXIDANTE Y NEUROPROTECTORA QUE CONSISTE EN LA MEZCLA DE EXTRACTO DE SHILAJIT ANDINO (250 A 500 MG) Y ÁCIDO FÓLICO (200 A 500 UG), JUNTO A PEQUEÑAS CANTIDADES DE VITAMINAS B6 (20 A 40 UG) Y B12 (4 A 8 UG) CON SUMIDAS POR DÍA. SE DIVULGA ADEMÁS EL MÉTODO DE FABRICACIÓN DE LA COMPOSICIÓN POR MEZCLA ALEATORIA DE SUS COMPONENTES.<br /> ESTA COMPOSICIÓN, SE ENCUENTRA EN FORMA DE LIOFILIZADO, CÁPSULAS, COMPRIMIDOS O GRAGEAS Y ES ÚTIL PARA LA PREVENCIÓN Y TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.<br /> LA COMPOSICIÓN ES APROPIADA PARA EL CONSUMO HUMANO DE MANERA DIRECTA POR VÍA ORAL, YA SEA EN FORMA SÓLIDA COMO POLVO O EN SUSPENSIÓN DEL EXTRACTO, COMO ADITIVO EN ALIMENTOS O COMO AGENTE NUTRACÉUTICO. PUEDE SER FORMULADA COMO UN AGENTE NUTRACÉUTICO INGREDIENTE DE BEBIDAS O COMO MEDICAMENTO JUNTO A EXCIPIENTES AUTORIZADOS.<br />  
CL2009001956A 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer. CL2009001956A1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.
CA2776919A CA2776919C (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing
GB1207939.8A GB2487871B (en) 2009-10-09 2010-10-08 Nutraceutical composition comprising extract of Andean shilajit, folic acid, vitamin B12 and vitamin B6
PCT/CL2010/000043 WO2011041920A2 (es) 2009-10-09 2010-10-08 Composición nutracéutica que comprende extracto de shilajit, ácido fólico, vitamina b12 y vitamina b6 y su uso para prevenir y/o tratar enfermedades neurodegenerativas y/o el deterioro cognitivo asociado al envejecimiento cerebral
US13/496,140 US8784804B2 (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging
AU2010305251A AU2010305251B2 (en) 2009-10-09 2010-10-08 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin B12 and Vitamin B6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Publications (1)

Publication Number Publication Date
CL2009001956A1 true CL2009001956A1 (es) 2010-06-04

Family

ID=43857199

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001956A CL2009001956A1 (es) 2009-10-09 2009-10-09 Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.

Country Status (6)

Country Link
US (1) US8784804B2 (es)
AU (1) AU2010305251B2 (es)
CA (1) CA2776919C (es)
CL (1) CL2009001956A1 (es)
GB (1) GB2487871B (es)
WO (1) WO2011041920A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107375A1 (es) 2013-12-20 2015-07-23 Vergara Campillo Ramiro Moises Combinación de piridoxina, ácido fólico y iones de magnesio para el tratamiento del cáncer
US20170295834A1 (en) * 2015-11-25 2017-10-19 Alexander LaCroix All-Natural Bitterness-Reducing Flavor System
KR20240132587A (ko) * 2023-02-27 2024-09-04 의료법인 명지의료재단 실라짓을 포함하는 알츠하이머성 치매 예방 및 치료용 조성물
CN118453638A (zh) * 2024-05-22 2024-08-09 中国人民解放军军事科学院军事医学研究院 一种营养组合物及其在线粒体功能损伤修复中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
US6440436B1 (en) * 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US6558712B1 (en) * 2001-09-21 2003-05-06 Natreon Inc. Delivery system for pharmaceutical, nutritional and cosmetic ingredients
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
US7250181B2 (en) * 2005-01-19 2007-07-31 Natreon, Inc. Polyherbal compositions and methods for treating viral infections

Also Published As

Publication number Publication date
WO2011041920A2 (es) 2011-04-14
AU2010305251A1 (en) 2012-05-31
US8784804B2 (en) 2014-07-22
GB201207939D0 (en) 2012-06-20
WO2011041920A3 (es) 2011-06-03
CA2776919C (en) 2015-07-14
US20120269794A1 (en) 2012-10-25
WO2011041920A8 (es) 2012-04-12
CA2776919A1 (en) 2011-04-14
AU2010305251B2 (en) 2013-12-19
GB2487871A (en) 2012-08-08
GB2487871B (en) 2017-04-05

Similar Documents

Publication Publication Date Title
CO6551760A2 (es) Polco de rifaximina , proceso para prepararlo y composiciones de liberación controlada que contiene dicha rifaeimina útil para obtener un efecto de larga duración
MX337408B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
UY32601A (es) Formulación en lípidos estabilizada de un promotor de la apoptosis
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
PE20121406A1 (es) Cepas de lactobacillus plantarum como agentes hipocolesterolemicos
BR112018014545A2 (pt) probióticos para uso como agentes anti-inflamatórios na cavidade oral
WO2012049222A3 (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
TN2015000135A1 (en) Modified release formulations for oprozomib
AR098653A1 (es) Composición útil para promover la fertilidad femenina, composición de combinación
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2009001956A1 (es) Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
MX2011011860A (es) Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc.
AR080052A1 (es) Composiciones que comprenden productos de azucar cisteina, bebida, contenedor de bebida, metodo
HRP20161447T1 (hr) Pripravak koji sadrži ekstrakt zelenog čaja i ekstrakt nara, namijenjen upotrebi u sprječavanju ili usporavanju napredovanja raka prostate
AR085265A1 (es) Composiciones farmaceuticas que contienen compuestos con selenita
CO6450623A2 (es) Parasiticidas sanguineos
MX387178B (es) Preparaciones de vitaminas que contienen galato de propilo.
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
GB2530226A (en) Chewable tablet
BR112014001728A2 (pt) fórmulas compreendendo elementos altamente solúveis e vitaminas para a prevenção e melhoria da osteoporose
AR089136A1 (es) Variantes de osteopontina para usar en la supresion o prevencion del crecimiento tumoral y composiciones que las contienen
PH12017501949A1 (en) Amyloid � fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid � fibril formation
WO2010142007A1 (pt) Composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
PH12016501553B1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations